Thymosin Beta-4 (Tβ4)

Thymosin beta-4 lands in the Strong recommend band because it is the most clinically tested peptide in its repair class, with the cleanest Phase 1 intravenous safety record among these peptides, the same broad tissue-repair mechanism buyers want from the TB-500 fragment, and strictly more human trial data than that fragment. What holds native Tβ4 just below the fragment is access rather than merit: FDA reclassified Tβ4 to a biologic in 2020, 2025 bulks-list actions closed the US compounding path, and most gray-market vials labeled TB-500 do not contain native full-length Tβ4 at all. The practical verdict splits by goal. For neurotrophic keratopathy patients who can access RGN-259 through a trial, the human signal is genuinely encouraging. For someone running an injury-recovery stack who can verify they hold actual full-length Tβ4 rather than mislabeled fragment, the mechanism and clean safety floor make it a strong add. For general recovery or longevity it is mostly mechanism plus anecdote. The Strong recommend score is honest because broad mechanism, a clean Phase 1 safety floor, and the largest human-trial base in the class pull Tβ4 well above neutral, while mixed Phase 3 efficacy endpoints and real sourcing friction keep it below the fragment and the top tier. Among gray-market repair peptides, native Tβ4 stands out for having actual Phase 1 IV safety data in healthy volunteers, with no dose-limiting toxicity up to 1,260 mg per day for 14 days. That is the cleanest human safety floor in this peptide class.Ruff 2010, Ann NY Acad Sci

✅ Best for: People recovering from a stubborn soft-tissue injury who want to add or substitute Tβ4 into a Wolverine-style BPC-157 stack for broader, less potent repair coverage than TB-500 alone. People with neurotrophic keratopathy who can access RGN-259 through a clinical trial, where SEER-1 showed a strong Phase 3 healing trend, per Sosne 2023. People with chronic poorly-healing wounds who are willing to work with a clinician and accept partial efficacy evidence. Research-minded users who can verify their material is genuine full-length Tβ4 with a certificate of analysis and third-party sequence confirmation, and who can monitor inflammation and tissue endpoints over a course. People who value the cleanest Phase 1 intravenous safety record in this peptide class.

❌ Avoid if: You have active or recent (within 5 years) cancer, since preclinical metastasis and angiogenesis signals are real and human tissue data correlate Tβ4 expression with worse cancer outcomes, per Cha 2003 and Oh 2016. You are pregnant, breastfeeding, or considering it for a child, where no human safety data exists. You are a tested athlete subject to WADA prohibition, which bans Tβ4 and its derivatives at all times with a 30 to 45 day detection window. You cannot verify your material is genuine 43-amino-acid Tβ4 rather than the TB-500 fragment, which is what most gray-market vials contain. You want general anti-aging or cognitive benefits, which the human trials never tested. You want an approved, regulated, pharmaceutical-grade option, which Tβ4 is not anywhere in the world.